Italy
Philogen S.p.A., founded in 1996, is a Swiss-Italian biotechnology company with a focus on developing advanced biopharmaceuticals aimed at treating disorders related to angiogenesis. Angiogenesis, the formation of new blood vessels, is a process commonly found in severe conditions like cancer, rheumatoid arthritis, and age-related macular degeneration.
Philogen has established itself as a pioneer, being the first to showcase that human monoclonal antibodies targeting angiogenesis can effectively target tumor neo-vasculature in both pre-clinical and clinical settings. Currently, the company is advancing four anti-cancer antibody derivatives and one for rheumatoid arthritis through clinical trials, with two registrational studies in the planning phase.
The R&D wing, Philochem, located in Zurich, is instrumental in isolating promising candidates, while manufacturing and further clinical developments occur in Siena, Italy, adhering to GMP standards. Philogen's revenue stems from diversified activities, strategic agreements with major pharmaceutical firms, and a robust international patent portfolio. The last significant financial milestone was a $68.84M IPO investment received on 01 March 2021.
MabVax Therapeutics, Inc.
